NCT06719973撤回1 期
An Open Label, Multicenter, Phase 1 Study of the PARP1 Inhibitor M9466 in Combination With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 54
- 主要终点
- Module 1 and Module 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 in combinations with carboplatin in advanced or metastatic refractory solid tumor and with the standard of care (carboplatin, etoposide, and atezolizumab) in treatment-naïve ES-SCLC. The results will support any investigation of carboplatin-based combination anticancer treatments with M9466 as well as the selection of a RP2D of M9466 in combination with carboplatin, etoposide, and atezolizumab for a subsequent ES-SCLC study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Module 1: Locally advanced or metastatic solid tumors that are refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator (that is [i.e.] participants who have exhausted all standard of care options according to International Guidelines), which may convey clinical benefit from the combination treatment with M9466 and carboplatin and have not received more than 3 lines of prior anticancer therapy in the advanced/metastatic setting Module 2: Histologically or cytologically confirmed treatment-naïve, de novo, extensive stage small cell lung cancer (ES-SCLC), who have no history of systemic treatment for the disease. Participant must be considered suitable to receive carboplatin, etoposide, and atezolizumab as first-line treatment for ES-SCLC
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) less than or equal to (<=) 1 (ECOG PS 2 eligible if considered related to SCLC tumor load in Module 2)
- •Have adequate hematological, hepatic, and renal function as defined in the protocol
- •Other protocol defined inclusion criteria could apply
排除标准
- •Module 1: Persistence of AEs related to any prior treatments that have not recovered to Grade <= 1 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 unless AEs are clinically non-significant and /or stable on supportive therapy in the opinion of the Investigator (for example [e.g.] neuropathy or alopecia)
- •Module 2: Participant has a history of malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, is considered cured with minimal risk of recurrence within 3 years)
- •Participants with known brain metastases, except if clinically controlled, which is defined as individuals with CNS tumors that are asymptomatic and who do not require steroids for the treatment of CNS tumors
- •Life expectancy of less than (<) 3 months
- •Other protocol defined exclusion criteria could apply
研究组 & 干预措施
Module 1 (Dose Finding): M9466 + Carboplatin
Experimental
干预措施: M9466 (Drug)
Module 1 (Dose Finding): M9466 + Carboplatin
Experimental
干预措施: Carboplatin (Drug)
Module 2 Part A (Dose Reassessment): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: Etoposide (Drug)
Module 2 Part A (Dose Reassessment): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: Atezolizumab (Drug)
Module 2 Part A (Dose Reassessment): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: M9446 (Drug)
Module 2 Part A (Dose Reassessment): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: Carboplatin (Drug)
Module 2 Part B (Dose Expansion): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: Etoposide (Drug)
Module 2 Part B (Dose Expansion): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: Atezolizumab (Drug)
Module 2 Part B (Dose Expansion): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: M9446 (Drug)
Module 2 Part B (Dose Expansion): M9466 + Carboplatin + Etoposide + Atezolizumab
Experimental
干预措施: Carboplatin (Drug)
结局指标
主要结局
Module 1 and Module 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs
时间窗: Time from signing Informed Consent Form (ICF) up to 30 days after end of study intervention (approximately assessed up to 24 months)
Module 1 and Module 2: Number of Participants with Dose-limiting Toxicity (DLT)
时间窗: Day 1 up to Day 21 of Cycle 1 (each cycle is of 21 days)
次要结局
- Module 1 and Module 2: Pharmacokinetic (PK) Plasma Concentration of M9466(Pre-dose up to 6 hours post-dose on Cycle 1 Day 1; Pre-dose on Cycle 1 Day 4 and Cycle 1 Day 8 (each cycle is of 21 days))
- Module 1 and Module 2: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) Assessed by Investigator(Time from first treatment of study intervention up to planned assessment at 24 months)
- Module 1 and Module 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Assessed by the Investigator(Time from first treatment of study intervention up to planned assessment at 24 months)
- Module 1 and Module 2: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Assessed by Investigator(Time from first treatment of study intervention up to planned assessment at 24 months)
研究者
相似试验
进行中（未招募）
1 期
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Advanced Solid TumorNCT06421935EMD Serono Research & Development Institute, Inc.60
已完成
1 期
Open Label Phase 1 Study in Japan for Patient With Advanced Solid MalignanciesAdvanced Solid MalignancyAdvanced Solid TumorNCT01353781AstraZeneca39
Unknown
1 期
A Study of SKLB1028 in Patients With Advanced Solid TumorAdvanced Solid TumorsNCT05072522CSPC ZhongQi Pharmaceutical Technology Co., Ltd.98
已完成
1 期
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal MelanomaUveal MelanomaChoroid NeoplasmNCT02771340Iconic Therapeutics, Inc.10
招募中
1 期
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06625593BeOne Medicines168